Did you mean: Annika Jarnefeldt
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
…, N Colclough, VP Reddy, A Sykes, A Janefeldt… - Science …, 2018 - science.org
Poor survival rates of patients with tumors arising from or disseminating into the brain are
attributed to an inability to excise all tumor tissue (if operable), a lack of blood-brain barrier (…
attributed to an inability to excise all tumor tissue (if operable), a lack of blood-brain barrier (…
Preclinical comparison of the blood–brain barrier permeability of osimertinib with other EGFR TKIs
…, P Barton, J Atkinson, L Zhang, A Janefeldt… - Clinical Cancer …, 2021 - AACR
Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of
both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood–…
both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood–…
[HTML][HTML] The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids
…, RM Mancina, D Lindén, C Whatling, A Janefeldt… - Scientific reports, 2019 - nature.com
There is a high unmet need for developing treatments for nonalcoholic fatty liver disease (NAFLD),
for which there are no approved drugs today. Here, we used a human in vitro disease …
for which there are no approved drugs today. Here, we used a human in vitro disease …
Structural and functional characterization of a specific antidote for ticagrelor
…, T Sjögren, L Öster, A Janefeldt… - Blood, The Journal …, 2015 - ashpublications.org
Ticagrelor is a direct-acting reversibly binding P2Y 12 antagonist and is widely used as an
antiplatelet therapy for the prevention of cardiovascular events in acute coronary syndrome …
antiplatelet therapy for the prevention of cardiovascular events in acute coronary syndrome …
Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell co-culture with plated …
B Bonn, P Svanberg, A Janefeldt, I Hultman… - Drug Metabolism and …, 2016 - ASPET
A key requirement in drug discovery is to accurately define intrinsic clearance (CL int )
values of less than 1 µl/min/10 6 hepatocytes, which requires assays that allow for longer …
values of less than 1 µl/min/10 6 hepatocytes, which requires assays that allow for longer …
[HTML][HTML] Primary human hepatocyte spheroid model as a 3D in vitro platform for metabolism studies
KP Kanebratt, A Janefeldt, L Vilén, A Vildhede… - Journal of …, 2021 - Elsevier
3D cultures of primary human hepatocytes (PHH) are emerging as a more in vivo-like culture
system than previously available hepatic models. This work describes the characterisation …
system than previously available hepatic models. This work describes the characterisation …
HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes
K Rubin, A Janefeldt, L Andersson, Z Berke… - Drug Metabolism and …, 2015 - ASPET
The suppression of hepatic cytochrome P450 (P450) expression during inflammatory and
infectious diseases and the relief of this suppression by successful disease treatment have …
infectious diseases and the relief of this suppression by successful disease treatment have …
Stapled Vasoactive Intestinal Peptide (VIP) Derivatives Improve VPAC2 Agonism and Glucose-Dependent Insulin Secretion
…, A Paunovic, C Priest, A Janefeldt… - ACS medicinal …, 2013 - ACS Publications
Agonists of vasoactive intestinal peptide receptor 2 (VPAC 2 ) stimulate glucose-dependent
insulin secretion, making them attractive candidates for the treatment of hyperglycaemia and …
insulin secretion, making them attractive candidates for the treatment of hyperglycaemia and …
[HTML][HTML] Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452
AS Sandinge, A Janefeldt, S Pehrsson, S Nylander - Plos one, 2018 - journals.plos.org
Ticagrelor, a P2Y 12 antagonist, is approved for prevention of thromboembolic events.
MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The …
MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The …
A specific antidote for ticagrelor
…, P Svensson, T Sjögren, L Öster, A Janefeldt… - Journal of the American …, 2015 - jacc.org
Background: A Fab, MEDI2452, is being developed as an antidote for ticagrelor patients
requiring urgent surgery or experiencing major or life-threatening bleeding where ticagrelor …
requiring urgent surgery or experiencing major or life-threatening bleeding where ticagrelor …
Did you mean to search for: Annika Jarnefeldt